ORGANIZATION

• At JPA’s Behest, FPMAJ Asks Members to Align Packaging with Approved Dosages
  May 19, 2025

• PhRMA Raps Japan’s Drug Price Controls as Non-Tariff Trade Barriers, Urges US Govt Action
  May 19, 2025

• PhRMA Questions Utility of Proposed Expert Committee for Patent Linkage
  May 8, 2025

• Generic Rate in Japan Reaches 89.3% at 2024-End: Payer
  May 8, 2025

• US Tariffs Would Hinder Access to Innovative Drugs: JPMA President
  April 24, 2025

• JPMA to Discuss Ways to Promote DX in Commercial Production in FY2025
  April 23, 2025

• New JPMA Task Force to Respond to ICH-GL and PMD Act Amendments
  April 22, 2025

• JPMA to Investigate the Status of Application of Japanese PI Waiver
  April 22, 2025

• PhRMA HTA Taskforce Warns CEA Expansion Will Accelerate Drug Loss in Japan
  April 18, 2025

• JPMA Sets Up Response Team to Collect Info on US Tariff Measures
  April 18, 2025

• Medical Advocacy Group Condemns Plan to Remove Coverage for OTC-Like Drugs
  April 17, 2025

• JGA to Release Interim Report on Industry Revamp in June: President
  April 14, 2025

• Contradictions in Drug Pricing System Can No Longer Be Overlooked: Ex-Bureaucrat
  April 10, 2025

• Pivot Away from Social Security Spending Cap: Labor Union to Govt
  April 10, 2025

• No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
  April 9, 2025

• Japan Generic Use Rate Vaults to 88.6% in October-December: JGA
  April 7, 2025

• JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
  April 2, 2025

• Iwaya Reappointed as EFPIA Japan Chair for 2-Year Term
  April 1, 2025

• Payer Kyokai Kenpo Ups Target for Biosimilar Use
  March 25, 2025

• FPMAJ Maps Out Planned Activities for FY2025
  March 24, 2025

ページ

• « 先頭
• ‹ Prev
• …
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• …
• Next ›
• 最終 »